Literature DB >> 16340718

Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?

David Fuster1, Stephen Chiang, Charalambos Andreadis, Liang Guan, Hongming Zhuang, Stephen Schuster, Abass Alavi.   

Abstract

OBJECTIVES: To assess the usefulness of [18F]fluorodeoxyglucose positron emission tomography in the detection of bone marrow involvement in malignant lymphoma, and its impact in clinical management.
METHODS: One hundred and six consecutive patients with a confirmed diagnosis of lymphoma, referred for staging or restaging of Hodgkin's lymphoma (n=18) or non-Hodgkin's lymphoma (n=88), were reviewed retrospectively. A positron emission tomography scan and bone marrow biopsy of the iliac crest were performed in all patients. The assessment of bone marrow involvement by lymphoma was confirmed by histology and/or progression of bone marrow lesions in clinical follow-up.
RESULTS: In 28 of 106 patients, bone marrow involvement was found. Positron emission tomography was more sensitive (86%) than bone marrow biopsy (57%). Positron emission tomography and bone marrow biopsy were concordant by positive correlation in 12 of 28 cases (43%) and by negative correlation in 77 of 78 cases (99%). Ten cases of non-Hodgkin's lymphoma and two cases of Hodgkin's lymphoma with positive positron emission tomography results and an initial negative bone marrow biopsy showed clinical progression of the bone marrow lesions and/or subsequent positive histology. These were considered as false-negative results for bone marrow biopsy. In seven of the 12 positive cases with negative bone marrow biopsy, positron emission tomography uptake distant from the site of the biopsy was seen. In four cases of follicular lymphoma, the bone marrow biopsy was positive and the positron emission tomography scan was normal.
CONCLUSIONS: Positron emission tomography and bone marrow biopsy are complementary in assessing the presence of bone marrow involvement in patients with malignant lymphoma. In our series, positron emission tomography was more sensitive than bone marrow biopsy in Hodgkin's and non-Hodgkin's lymphoma, except in follicular lymphoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16340718     DOI: 10.1097/01.mnm.0000185000.81203.49

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  10 in total

Review 1.  Discordant bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Jennifer Brudno; Tamar Tadmor; Stefania Pittaluga; Alina Nicolae; Aaron Polliack; Kieron Dunleavy
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

2.  Usefulness of (18)F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma.

Authors:  Yukyung Lee; Kyung Hoon Hwang; Junshik Hong; Jinny Park; Jae Hoon Lee; Jeong Yeal Ahn; Ji Hyun Kim; Haejun Lee; Seog Gyun Kim; Ji Young Shin
Journal:  Nucl Med Mol Imaging       Date:  2012-07-18

3.  Clinical utility of ¹⁸F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma.

Authors:  S Muzahir; M Mian; I Munir; M K Nawaz; Z S Faruqui; K A Mufti; H Bashir; N Uddin; N Siddiqui; A U R Maaz; M T Mahmood
Journal:  Br J Radiol       Date:  2012-01-03       Impact factor: 3.039

4.  Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients.

Authors:  Gang Cheng; Wengen Chen; Wichana Chamroonrat; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-20       Impact factor: 9.236

5.  The utility of body FDG PET in staging primary central nervous system lymphoma.

Authors:  Nimish A Mohile; Lisa M Deangelis; Lauren E Abrey
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

6.  Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate.

Authors:  Gaetano Paone; Emmanuel Itti; Corinne Haioun; Philippe Gaulard; Jehan Dupuis; Chieh Lin; Michel Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

7.  Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

Authors:  E Pelosi; P Pregno; D Penna; D Deandreis; A Chiappella; G Limerutti; U Vitolo; M Mancini; G Bisi; E Gallo
Journal:  Radiol Med       Date:  2008-04-14       Impact factor: 3.469

8.  Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era - tissue remains the issue.

Authors:  Suchitra Sundaram; Mazen Jizzini; Dominick Lamonica; Kristopher Attwood; Matthew Gravina; Francisco Hernandez-Ilizaliturri; Pallawi Torka
Journal:  Leuk Lymphoma       Date:  2020-08-04

9.  Revisiting the Marrow Metabolic Changes after Chemotherapy in Lymphoma: A Step towards Personalized Care.

Authors:  Bingfeng Tang; Malaykumar M Patel; Regina H Wong; Daniel Wood; Christiana O Wong; Dafang Wu; Pek Lan Khong; Ching Yee Oliver Wong
Journal:  Int J Mol Imaging       Date:  2011-09-28

10.  Efficacy of 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computerized Tomography for Bone Marrow Infiltration Assessment in the Initial Staging of Lymphoma.

Authors:  Ali Ozan Öner; Evrim Sürer Budak; Funda Aydın; Ozan Salim; Orhan Kemal Yücel; Bahar Akkaya; Tayfur Toptaş; Adil Boz; Akın Yıldız; Fırat Güngör; Levent Undar
Journal:  Mol Imaging Radionucl Ther       Date:  2017-06-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.